Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 22, 2023 Category: Pharmaceuticals Source Type: news
7 Blue-Chip Dividend Stocks to Buy Before Dec. 31
Always a string investment, blue-chip dividend stocks continue to make sense as 2023 draws closer to and end It’s always a good time for investors to consider investing in blue-chip dividend stocks. In a sense, this class of equities is amongst the most established and stable investments possible.…#mcdonalds #mcdonald #cosmc #starbucks #federalreserves #avgo #broadcom #humira #sassumed #abbviecontinues (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2023 Category: Consumer Health News Source Type: news
Better Income Stock: AT & T or AbbVie?
Dividend stocks can offer a valuable source of income for investors who want to diversify their portfolios. However, investors should also be aware that most of these stocks will gradually decline in value over time unless the dividend is reinvested. This may seem surprising, but ample evidence…#dividend #att #abbvie #abbottlaboratories #dividendking #sprint #humira #imbruvica #georgebudwell #motleyfool (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2023 Category: Consumer Health News Source Type: news
3 of the Most Attractive Dividend Stocks in the Pharma Space
Pharma dividend stocks efficiently merge healthcare innovation with reliable dividends for long-term value In the realm of investment, pharma dividend stocks are a beacon for both stability and growth. This sector not only enhances the quality of life on a global scale but also presents lucrative…#pharma #abbvie #humira #skyrizirinvoqvraylar #botox #rinvoq #johnsonjohnson #kenvue #yoy #fcf (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2023 Category: Consumer Health News Source Type: news
$19 Billion in a Week: AbbVie Makes Two Big Bets
Early last week, AbbVie was on every healthcare investment banker’s list. But with two quick deal announcements under its belt in just six days, AbbVie may have transformed its pipeline in cancer and neurology and satiated its deal-making hunger. The Chicago-area company, best known for selling…#abbvie #humira #immunogen #cereveltherapeutics (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2023 Category: Consumer Health News Source Type: news
Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System
Impediments to biosimilar access prevent market competition from working properly, raise patient cost-sharing and harm long-term sustainability of biosimilar development. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 4, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today ’s Economy
These are the best blue-chip stocks for investors to consider Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be tomorrow. Today’s economy is marked by a…#openai #nvidia #h100 #h200 #nvda #pfas #3m #abbvie #humira #rinvoq (Source: Reuters: Health)
Source: Reuters: Health - November 30, 2023 Category: Consumer Health News Source Type: news
Samsung Bioepis Marks a New Chapter in the Biosimilar Industry with Groundbreaking Advancements, Exclusive Interview by Xtalks
In an interview by Xtalks, company leaders at Samsung Bioepis, Ilsun Hong and Thomas Newcomer, discuss the company's advancements in the biosimilar industry. They discuss the FDA approval for both high- and low-concentration formulations of their adalimumab biosimilar and the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 29, 2023 Category: Pharmaceuticals Tags: PDT Source Type: news
3 Rising Stars: Invest Now in Tomorrow ’s Trillion-Dollar Companies
As the global economic landscape evolves, identifying burgeoning companies with potential to scale into trillion-dollar entities is a pursuit that captivates investors worldwide. In the realm of pharmaceuticals, technology, and semiconductor manufacturing, three standout enterprises are reshaping…#abbvie #humira #skyrizirinvoqvraylar #botox #rinvoq #crohn #usinternational #abbv #eps #tsmc (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2023 Category: Consumer Health News Source Type: news
The Best 7 Dividend Stocks to Own in Retirement
While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S. government to provide for your needs is not the best idea. The full retirement age is 66 if you were born between 1943 and 1954. The full retirement age increases gradually if you were born between…#abbvie #abbvieinc #abbottlaboratories #humira #allerganplc #allergan #botox #chevron #chevroncorporation #cvx (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2023 Category: Consumer Health News Source Type: news
7 High-Yield Blue Chips Suitable for Any Retiree
High-yield blue-chip stocks are appropriate for every retirement portfolio Before extolling the benefits of high-yield blue-chip stocks, it’s important to acknowledge the reality that many investors are feeling. Long-term stock investors have had to muddle through challenging macroeconomic…#abbvie #humira #rinvoq #abbv #dividendking #johnsonjohnson #jnj #dukeenergy #duke #florida (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2023 Category: Consumer Health News Source Type: news
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA ™…
sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued group • Filing acceptance reinforces Samsung Bioepis and Organon's commitment to provide better…#phase4 #humira #samsungbioepis #organon #incheon #jerseycity #samsungbioepiscoltd #organonco #ogn #fda (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2023 Category: Consumer Health News Source Type: news
AbbVie (NYSE:ABBV) Exceeds Q3 Expectations; Hikes Dividend - TipRanks.com
Pharmaceutical behemoth AbbVie (NYSE:ABBV) delivered a better-than-anticipated third-quarter performance, with EPS of $2.95 outpacing expectations by $0.08. Revenue of $13.93 billion also fared better than the consensus by $220 million, despite a year-over-year decline of 5.9%. During the quarter,…#eps #immunology #humira #skyrizi #rinvoq #abbviesoncology #imbruvica #vraylar #ubrelvy #botox (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
AbbVie Lifts Profit Outlook as Newer Biologics Help Buffer Dwindling Humira Sales
(Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
AbbVie raises profit forecast after Humira, newer drugs drive results beat
The logo for AbbVie is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Oct 27 (Reuters) - AbbVie (ABBV.N) on Friday raised its annual profit forecast after beating quarterly…#abbvie #newyorkcity #humira #sandoz #amgen #boehringeringelheim #rinvoq #imbruvica (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
